ARVO LIVE: OTT166 in the treatment of diabetic retinopathy

Video
Conferences|ARVO

Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.

Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Recent Videos
Related Content
Richard Rosen, MD, honored with distinguished award from ASRS

Richard Rosen, MD, honored with distinguished award from ASRS

Article
Highlighting results from first FDA-reported study for treatment of presbyopia

Highlighting results from first FDA-reported study for treatment of presbyopia

Podcast
ASRS 2024: TEASE-3 study data shows progression stalled in early-stage Stargardt disease patients treated with gildeuretinol

ASRS 2024: TEASE-3 study data shows progression stalled in early-stage Stargardt disease patients treated with gildeuretinol

Article
EYEPOD: Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients.

Impact of prior authorization for cataract surgery

Podcast
ASRS 2024: Adverum Biotechnologies presenting positive Ixo-vec clinical data from the 26-week interim analysis of the LUNA Phase 2 trial

ASRS 2024: Adverum Biotechnologies presenting positive Ixo-vec clinical data from the 26-week interim analysis of the LUNA Phase 2 trial

Article
ASRS 2024: A look into premier meeting for retina science and innovation

ASRS 2024: A look into premier meeting for retina science and innovation

Article
© 2024 MJH Life Sciences

All rights reserved.